Nishimura R, Kobayashi K, Katsuno M, Kobayashi T
Department of Obstetrics and Gynecology, Hyogo Medical Center for Adults.
Nihon Sanka Fujinka Gakkai Zasshi. 1990 Feb;42(2):143-8.
In addition to human chorionic gonadotropin (hCG) and its free subunits, low molecular weight hCG beta-related fragments have been previously demonstrated in pregnancy urine and in the urine of patients with trophoblastic and nontrophoblastic tumors. The urinary beta-core fragment in particular is focused on as a new tumor marker in gynecological malignancies. We developed an EIA for the beta-core fragment using the monoclonal antibody (MoAb229) which specifically recognized the core portion of hCG beta. By measuring with MoAb229-EIA, it was clearly revealed that urine obtained from normal pregnant women as well as from patients with choriocarcinoma and nontrophoblastic ovarian cancer contains a large amount of the beta-core fragment when separated on Sephadex G-100. We conclude that our MoAb229-EIA is a useful tool to use in detecting the beta-core fragment, a new tumor marker, in the urine of gynecological cancer patients.
除了人绒毛膜促性腺激素（hCG）及其游离亚基外，低分子量hCGβ相关片段先前已在妊娠尿液以及滋养层和非滋养层肿瘤患者的尿液中得到证实。尤其是尿β核心片段作为妇科恶性肿瘤的一种新的肿瘤标志物受到关注。我们使用特异性识别hCGβ核心部分的单克隆抗体（MoAb229）开发了一种针对β核心片段的酶免疫分析方法。通过用MoAb229-酶免疫分析进行检测，清楚地显示，当在葡聚糖凝胶G-100上分离时，正常孕妇以及绒毛膜癌和非滋养层卵巢癌患者的尿液中含有大量的β核心片段。我们得出结论，我们的MoAb229-酶免疫分析是检测妇科癌症患者尿液中新型肿瘤标志物β核心片段的有用工具。
